Beginnings of Personalized Medicine for Myeloma

Ajai Chari, MD
Video Categories: Personalized Medicine

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
April 14, 2015

CancerTYPE ID in the Clinic

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.

October 7, 2016

Common Issues in Treating Patients with HR+/ HER2-Negative Metastatic Breast Cancer

Dr Hope Rugo discusses some of the choices and challenges she’s faced with in treating patients with HR+/ HER2-negative metastatic breast cancer with the goal of helping patients live as long as possible and with the best quality of life.